Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3439539 in Symptomatic Alzheimer's Disease
NCT07598370Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of LY3439539 in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Primary endpoint: Cerebrospinal Fluid Neurofilament Light Chain at 24 weeks. Started May 2026; status: recruiting.
02
Drugs
LY3439539
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07598370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598370.